Navigo Proteins GmbH, based in Halle, is a biotechnology company 90% owned by UV-Cap and 10% by evo-partners, focused on research, development, production and sales of biochemical substances, notably proteins. Navigo operates two business units: “Precision Capturing”, developing ligands for affinity chromatography and providing customer-specific development services, and “Precision Targeting”, developing binders as therapeutics for radio-diagnostics and radiotherapy. In Precision Capturing, Navigo generated development-service revenues of TEUR 2,069 and invested in equipment, personnel and an ISO certification process in 2024 (certification completed in 2025) while developing its own ligands and resins. The company employed on average 74 people (73 at year-end 2024), incurred R&D expenses of approx. EUR 6.5 million in 2024 (about 55% of total costs; 47% of revenues) and held a 71.2% stake in OPTIGO Biotherapeutics Inc. as of 31 Dec 2024.
Die Erforschung, Entwicklung, Herstellung sowie der Vertrieb von biochemischen und chemischen Substanzen, insbesondere von Proteinen, sowie die Durchführung von Forschungs- und Entwicklungsarbeiten und das Leisten von ähnlichen Diensten für Dritte sowie alle sonst damit zusammenhängenden Tätigkeiten.
Converted using the official Destatis and Eurostat correspondence tables; ISIC Rev. 4 is the United Nations' international industry classification.
This summary was generated with the help of AI. See our Data Quality Notice. Report error?
Source: German Commercial Register (Handelsregister) Stendal Local Court, HRB 212705 (as of 1 November 2026)
| Name | Type | City |
|---|---|---|
| Henning Afflerbach | Geschäftsführer(in) | Düsseldorf |
| Chris-Carol Bremer | Geschäftsführer(in) | Seelze |
| Ulrich Haupts | Geschäftsführer(in) | Odenthal |
| Andreas Richter | Geschäftsführer(in) | Meerbusch |
Source: German Commercial Register (Handelsregister) Stendal Local Court, HRB 212705 (as of 1 November 2026)
| Date | Event Type | Event |
|---|---|---|
| 20.04.2018 | Gesellschaftsvertrag amended | Gesellschaftsvertrag |
| 21.12.2017 | Gesellschaftsvertrag amended | Gesellschaftsvertrag |
| 13.03.2017 | Company Name Change | Navigo Proteins GmbH |
| Date | Type | Change | Total Capital |
|---|---|---|---|
| 20.04.2018 | Capital Decrease | -870.000 € | 610.000 € |
| 21.12.2017 | Capital Decrease | -7.920.000 € | 1.480.000 € |
| 20.05.2008 | Capital Increase | +1.500.000 € | 9.400.000 € |
Source: German Commercial Register (Handelsregister) Stendal Local Court, HRB 212705 (as of 1 November 2026)
| Year | Revenue | Profit | Balance | Employees |
|---|---|---|---|---|
| 2024 | Rohergebnis€12.2M2 | €2,370,115 | €19,652,663 | — |
| 2023 | Rohergebnis€11M2 | €1,464,951 | €17,874,906 | — |
| 2022 | Rohergebnis€10.3M2 | €1,514,790 | €16,764,888 | — |
| 2021 | Rohergebnis€7.6M2 | €1,431,937 | €12,218,881 | — |
| 2020 | ≤ €12M1 | — | €10,583,460 | — |
| 2019 | ≤ €12M1 | €0 | €9,449,474 | — |
| 2018 | small company1 | -€1,097,244 | €3,167,621 | — |
| 2017 | small company1 | — | €2,245,547 | — |
| 2016 | small company1 | — | €2,189,417 | — |
| 2015 | €51,285 | -€3,537,389 | €2,067,542 | — |
1 Small companies are not required to publish a profit-and-loss statement (§ 326 (1) HGB). The figure shown is the statutory ceiling under § 267 HGB where the balance-sheet total makes it binding — a company may exceed at most one of the three size criteria.
2 Rohergebnis nach § 276 HGB: Umsatzerlöse abzüglich Materialaufwand bzw. Herstellungskosten. Kleine und mittelgroße Kapitalgesellschaften dürfen diese Posten zusammenfassen; die Umsatzerlöse selbst sind dann nicht veröffentlicht und liegen über dem Rohergebnis.
Sign in to download data
Source: German Commercial Register (Handelsregister) Stendal Local Court, HRB 212705 (as of 1 November 2026)
| Cost type | Amount | Share |
|---|---|---|
| Personnel Costs | €5,976,232 | 88.9% |
| Depreciation | €620,505 | 9.2% |
| Interest & Similar | €126,153 | 1.9% |
